Two groups each of 38 women with cultures positive for Candida on Sabouraud’s medium were studied. One group was given terconazole 0.8% cream for 5 days and the other clotrimazole 1% cream for 6 days. 1 week after treatment cultures from the whole terconazole group were negative for Candida, whereas one in the clotrimazole group was still positive and remained so after 4 weeks. Before treatment 27, 31, and 33 women in the terconazole groups, and 27, 33, and 35 subjects in the clotrimazole group suffered from pruritus, burning and discharge, respectively. 1 week after treatment pruritus and burning had subsided in all women in the terconazole group, but were still present in 3 and 5 patients, respectively, in the clotrimazole group. By that time 10 women on terconazole and 14 on clotrimazole still complained of vaginal discharge. 4 weeks after treatment 1 woman on clotrimazole suffered from pruritus and 2 subjects on terconazole from burning; discharge was still present in 9 patients on terconazole and in 8 on clotrimazole. Results of treatment after 1 week and 4 weeks were considered good to very good for all cases on terconazole and for 37 on clotrimazole; the results for 1 patient on clotrimazole were considered poor. 6 patients on clotrimazole reported burning following application of the cream. To increase the acceptability of antifungal treatment, those drugs with the fewest side-effects, such as burning or unpleasant odour, and which are easiest to apply should be prescribed.

Keywords:
Clotrimazole, Terconazole, Vulvovaginal candidosis
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.